SCHEMBL6140809

SCHEMBL6140809

Brc1cccc(Cc2cc3ccccc3o2)c1.O=Cc1cc2ccccc2o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 2/20 0.57
SLC5A2 P31639 1/20 0.42
MAOB P27338 3/20 0.42
MAOA P21397 2/20 0.42
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
TSHR P16473 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41
NLRP3 Q96P20 1/20 0.41
LOXL2 Q9Y4K0 1/20 0.40
HTR2B P41595 3/20 0.39
HTR1A P08908 2/20 0.39
AGXT P21549 1/20 0.38
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL154626 0.88 MAOB (0.51) SLC5A2MAOBMAOARAB9ANPC1
SCHEMBL29087527 0.76 LOXL2 (0.53) CYP2A6SLC5A2MAOBMAOATP53
SCHEMBL7806512 0.76 LOXL2 (0.60) CYP2A6SLC5A2RAB9ANPC1TSHR
SCHEMBL9956377 0.76 CYP2A6 (1.00) CYP2A6MAOBRAB9ANPC1TSHR
SCHEMBL91009 0.76 CYP2A6 (1.00) CYP2A6MAOBRAB9ANPC1TSHR
SCHEMBL29502957 0.76 CYP2A6 (1.00) CYP2A6MAOBRAB9ANPC1TSHR
SCHEMBL17398481 0.76 ALDH1A1 (0.46) CYP2A6MAOBMAOATSHRAGXT
SCHEMBL1601958 0.72 PIM1 (0.50) CYP2A6RAB9ATSHRTP53MAPK1
Acetaldehyde SCHEMBL6272809 0.71 CYP2A6 (0.89) CYP2A6MAOBMAOARAB9ANPC1
SCHEMBL17398298 0.69 RXRA (0.41) CYP2A6MAOBMAOAAGXTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050233988-A1 Novel compounds TANABE SEIYAKU CO., LTD. (JP) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050233988-A1 Novel compounds CYP1B1, CYP4B1, CYP2B6 CYP2A6 48/4885SLC5A2 472/4885MAOB 171/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.